Acasti Pharma (ACST) Reports Q1 Loss of $0.18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Acasti Announces Fourth Quarter and Fiscal Year Results
May 25, 2016 5:01 PM EDTLAVAL, QUEBEC -- (Marketwired) -- 05/25/16 -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars.
"As announced recently, we are delighted with the arrival of our new CEO next week, Ms. Jan D'Alvise's. With her... More
Neptune Announces Fourth Quarter and Fiscal Year Results
May 25, 2016 5:00 PM EDTLAVAL, QUEBEC -- (Marketwired) -- 05/25/16 -- Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT)(TSX: NTB)
Q4 Financial and Operational Highlights (1):
-- Revenues of $10.0 million, up 161% versus last year -- Gross margin on sales rose to 27% -- Nutraceutical segment generated positive Adjusted EBITDA of $658,000 compared to a loss of $7.8 million a year ago -- Q4 closing cash balance of $3.5 million -- Realized 50% of $5.0 million cost savings plan -- Canada now one of only two countries that can export krill oil to China opening new opportunities -- Neptune receives first Chinese... More